Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Biogen Idec Inc. : Biogen 4th-Quarter Profit Falls 2.7% on Higher Costs; Revenue Up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/28/2013 | 01:13pm CEST
   By Tess Stynes and Melodie Warner 
 

Biogen Idec Inc.'s (BIIB) fourth-quarter earnings fell 2.7% as the biotechnology company's efforts to bulk up its product pipeline masked its revenue growth.

The company also forecast 2013 adjusted earnings of $7.15 to $7.25 a share on about 10% revenue growth. Analysts surveyed by Thomson Reuters expect $7.27 a share on a 9% rise in revenue to $5.98 billion.

Biogen on Thursday said a new version of its blockbuster multiple-sclerosis drug Avonex was successful in a late-stage trial, strengthening the company's stable of drugs for the degenerative nerve disease. However, the overall market for such injectable drugs is expected to decline sharply amid a growing market for oral-pill-based drugs. Biogen's own BG-12 pill could be approved and launched in the U.S. as soon as March.

Biogen has been beefing up its sales force and readying its manufacturing supply chain as some drugs in its late-stage product pipeline have been drawing closer to entering the market.

Research and development costs rose 1.8% in the latest period while selling, general and administrative costs jumped 32%.

Biogen reported a profit of $292.1 million, or $1.23 a share, down from $300.2 million, or $1.22 a share, a year earlier. Excluding items such as stock-option expense, amortization and restructuring charges, per-share earnings fell to $1.40 from $1.51. Revenue increased 6.9% to $1.42 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.46 a share on revenue of $1.39 billion.

In the latest quarter, sales of Avonex rose 7.1% to $753.2 million.

Shares closed Friday at $146.20 and were inactive premarket. The stock is up 23% over the past year.

Write to Tess Stynes at [email protected] and Melodie Warner at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOGEN
09/12 BIOGEN : Appoints Sanjay Jariwala as SVP, Worldwide Medical
09/06 BIOGEN : to Present at the Morgan Stanley 15th Annual Global Healthcare Conferen..
08/28 BIOGEN : Featured Company News - IMRALDI(R), Biogen's Version of AbbVie's Humira..
08/28 BIOGEN : Reports New Data from Phase 1b Study of Investigational Alzheimer&rsquo..
08/25 Samsung, Biogen version of AbbVie's Humira approved in Europe
08/25 BIOGEN : IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is ..
08/18DJCorrection to Biogen Treads Tricky Path Between Politicians, Investors Articl..
08/17 BIOGEN : Today's Research Reports on Stocks to Watch: Biogen Inc. and MannKind C..
07/31 BIOGEN : Appoints Anabella Villalobos Senior Vice President, Biotherapeutic & Me..
07/28 ABARCA HEALTH : Announces Innovative Value-Based Contract With Biogen For Multip..
More news
News from SeekingAlpha
09/21 FDA's Woodcock says clinical trials system "broken"
09/21 Premarket analyst action - healthcare
09/20 Premarket analyst action - healthcare
09/19 Biotech And Pharma Stocks To Soak Up At The Bottom
09/12 FDA accepts Sandoz's marketing application for Rituxan biosimilar
Financials ($)
Sales 2017 11 937 M
EBIT 2017 6 168 M
Net income 2017 3 905 M
Debt 2017 3 268 M
Yield 2017 -
P/E ratio 2017 17,62
P/E ratio 2018 15,02
EV / Sales 2017 5,92x
EV / Sales 2018 5,51x
Capitalization 67 447 M
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 333 $
Spread / Average Target 4,4%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alisha A. Alaimo Senior Vice President-US Therapeutic Operations
Gregory F. Covino VP-Finance, Chief Financial & Accounting Officer
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN22.93%67 447
CSL LIMITED30.43%48 470
ALEXION PHARMACEUTICALS19.89%31 898
GRIFOLS SA25.95%17 183
BIOMARIN PHARMACEUTICAL10.95%16 225
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%6 193